Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;25(2):100298.
doi: 10.1016/j.clinme.2025.100298. Epub 2025 Feb 22.

GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence

Maria S Varughese  1 , Fidelma O'Mahony  2 , Lakshminarayanan Varadhan  3
Affiliations

GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence

Maria S Varughese et al. Clin Med (Lond). 2025 Mar.

Abstract

The prevalence of type 2 diabetes mellitus (T2DM) and obesity is increasing in young adults, posing significant risks around pregnancy. Obesity also impacts on fertility and the co-existence of polycystic ovarian syndrome increases the prevalence of cardiovascular metabolic risk factors. There has been a renewed interest in glucagon-like peptide-1 receptor agonists (GLP-1RA) in this context, due to their multi-dimensional impact on the reproductive axis, as well as their ability to simultaneously target weight loss and glycaemic control. There is, however, limited availability of safety data with respect to these newer non-insulin-based diabetes medications from the perspective of fetal development. As GLP-1RA are not licensed for use in pregnancy, with the increasing chances of incidental exposure from pre-conception use for obesity and T2DM, it is imperative that pre-conception counselling should be an integral part of consultation prior to the initiation of these drugs.

Keywords: Fetal medicine; GLP-1 receptor agonist therapy; Pregnancy; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Cho N.H., Shaw J.E., Karuranga S., et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. - PubMed
    1. Cesta C.E., Cohen J.M., Pazzagli L., et al. Antidiabetic medication use during pregnancy: an international utilization study. BMJ Open Diabetes Res Care. 2019;7(1) - PMC - PubMed
    1. American Diabetes Association Professional Practice Committee 15. Management of diabetes in pregnancy: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S282–S294. - PMC - PubMed
    1. Jensterle M., Janez A., Fliers E., DeVries J.H., Vrtacnik-Bokal E., Siegelaar SE. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019;25(4):504–517. - PubMed
    1. Cena H., Chiovato L., Nappi RE. Obesity, polycystic Ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020;105(8):e2695–e2709. - PMC - PubMed

Substances